HOXA5 is a key regulator of class 3 semaphorins expression in the synovium of rheumatoid arthritis patients
Authors' conclusion
HOXA5 expression is reduced during the progression of RA and could be a novel therapeutic strategy for modulating the hyperplasia of the synovium, through the regulation of class 3 semaphorins expression.
Study context
- Population
- Synovial tissue from RA and individuals at risk (IAR) patients; Human umbilical vein endothelial cells (HUVEC) and RA fibroblast-like synoviocytes (FLS)
- Comparison
- RA vs individuals at risk (IAR) synovium; HOXA5, TCF-3, EBF-1 silencing in FLS and HUVEC
- Outcome
- Transcription factors involved in the expression of class 3 semaphorins in the synovium of RA patients
Methodological detailsin silico analysis, siRNA knockdown
- In silico analysis
- siRNA knockdown
Main finding
As reported in the abstract
- mRNA expression of all class 3 semaphorins significantly lower in RA vs IAR synovium
- In silico analysis suggested TCF-3, EBF-1 and HOXA5 as transcription factors involved in their expression
- TCF-3, EBF-1 and HOXA5 silencing significantly reduced expression of several class 3 semaphorins in FLS and HUVEC
- HOXA5 expression significantly reduced in RA vs IAR synovium and negatively correlated with clinical disease parameters
- TNF-α down-regulated HOXA5 expression in FLS and HUVEC
- HOXA5 silencing enhanced migratory and invasive capacities of FLS and viability of HUVEC
Original publication
HOXA5 is a key regulator of class 3 semaphorins expression in the synovium of rheumatoid arthritis patients. Rheumatology (Oxford). Published 18 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →